NYSE - Delayed Quote USD

Penumbra, Inc. (PEN)

280.68
+5.36
+(1.95%)
At close: May 16 at 4:00:02 PM EDT
279.00
-1.68
(-0.60%)
After hours: May 16 at 6:40:00 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Adam Elsesser J.D. Co-Founder, Chairman, President & CEO 630.47k 1.21M 1962
Dr. Arani Bose M.D. Co-Founder & Director 54k -- 1962
Ms. Maggie S. Yuen Chief Financial Officer 706.8k -- 1972
Mr. Lambert Shiu Chief Accounting Officer 581.47k 1.22M 1980
Ms. Johanna Roberts J.D. Executive VP, General Counsel & Secretary 706.47k 294.98k 1972
Mr. Ben Sorci Executive Vice President of Operations -- -- --
Mr. Pankaj Tiwari Executive VP & Chief Information Officer -- -- --
Ms. Jee Hamlyn-Harris Investor Relations Officer -- -- --
Mr. Ben Tompkins Executive Vice President of Development & Compliance -- -- --
Ms. Shruthi Narayan President of Interventional -- -- --

Penumbra, Inc.

One Penumbra Place
Alameda, CA 94502
United States
510 748 3200 https://www.penumbrainc.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
4,500

Description

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Corporate Governance

Penumbra, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 7. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 7; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

July 28, 2025 at 10:59 AM UTC - August 1, 2025 at 12:00 PM UTC

Penumbra, Inc. Earnings Date

Recent Events

April 23, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 16, 2025 at 12:00 AM UTC

DEF 14A: Proxy Statements

April 4, 2025 at 12:00 AM UTC

PRE 14A: Proxy Statements

February 21, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 18, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

November 14, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

October 30, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 25, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

September 17, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

August 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers